否决细胞与免疫耐受的诱导
摘要
骨髓、外周血和胸腺内有一些细胞,能特异地杀灭识别其表面抗原的前体细胞毒T细胞(CTLP)这些细胞称为否决细胞。CTL是引起排斥反应的主要细胞,所以杀灭受体CTL可使宿主与移植物间长期相互接受,产生免疫耐受。
出处
《实用临床医学（江西）》
CAS
2006年第2期145-146,148,共3页
Practical Clinical Medicine
参考文献17
-
1Starzl T E.Chimerism and Donor-specific Nonreactivity 27 to 29 Years after Kidney Allotransplantation[J].Transplantation,1993,55(6):1 272-1 277. 被引量：1
-
2Davison G M.Immune Reconstitution after Allogeneic Bone Marrow Transplatation Depleted of Tcells[J].Transplantation,2000,69:1 341-1 347. 被引量：1
-
3Reisner Y,Martelli M F.Bone Marrow Transplantation Across HLA Barriers by Increasing the Number of Transplanted Cells [J].Immunol Today,1995,16 :437-440. 被引量：1
-
4Bachar-Lustig E,Li H W,Gur H,et al.Induction of Donortype Chimerism and Transplantation Tolerance Across Major Histocompatibility Barriers in Sublethally Irradiated Mice by Sca-1(+) Lin(-) Bone Marrow Progenitor Cells:Synergism with Nonalloreactive (Host x Donor)F(1) T Cells[J].Blood,1999,94:3 212-3 221. 被引量：1
-
5Miller R G.An Immunological Suppressor Cell Inactivating Cytotoxic T-lymphocyte Precursor Cells Recognizing It[J].Nature,1980,287 :544- 546. 被引量：1
-
6Zhang L,Shannon J,Sheldon J,et al.Role of Infused CD8+ Cells in the Induction of Peripheral Tolerance[J].J Immunol,1994,152:2 222-2 228. 被引量：1
-
7Bachar-Lusting E,Reisner Y.Anti-third-party Veto CTLs Overcome Rejection of Hematopoietic Allografts:Synergism with Rapamycin and BM Cell Dose[J].Blood,2003,102:1 943- 1 950. 被引量：1
-
8Sambhara S R,Miller R G.Reduction of CTL Anti-peptide Response Mediated by CD8^+ Cells Whose Class I MHC Can Bind the Peptide[J].J Immunol,1994,152:1 103-1 109. 被引量：1
-
9Reich-Zeliger S,Zhao Y,Krauthgamer R,et al.Anti-third Party CD8^+ CTLs as Potent Veto Cells:Coexpression of CD8 and FasL is a Prerequisite[J].Immunity,2000,13:507- 515. 被引量：1
-
10Qi Y,Berg R,Singleton M A,et al.Hybrid Antibody Mediated Veto of Cytotoxic T Lymphocyte Responses [J].J Exp Med,1996,183:l 973-1 996. 被引量：1
二级参考文献8
-
1Nold RJ, Beamer RL, Helmer SD, et al. Factors influencing a women's choice to undergo to breast-conserving surgery versus modified radical mastectomy [J]. Am J Surg, 2000,180(6) :413. 被引量：1
-
2Bonadonna G, Valagussa P, Brambilla C, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute[J]. J Clin Oncol, 1998,16(1) :93. 被引量：1
-
3Burke MF, Allison R, Tripcony L, et al. Conservative therapy of breast cancer in queensland[J]. Int J Radiat Oncol Biol Phys, 1995,31(2) .295. 被引量：1
-
4Weber S,Storm FK, Stitt J,et al. The role of frozen section analysis of margins during breast conservation surgery[J]. Cancer J Sci Am, 2000,6 (1) ; 28. 被引量：1
-
5Kearney TJ, Morrow M. Effect of reexcision on the success of breast conserving surgery [J]. Ann Surg Oncol,1995,2(4) :303. 被引量：1
-
6Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer:influence of margin status and systemic therapy on local recurrence[J]. J Clin Oncol. 2000. 18(8), 1668. 被引量：1
-
7于金明,李建彬,孙敏,魏守杰,左文述,王永胜.乳腺癌保留乳房术后放射治疗58例[J].中华放射肿瘤学杂志,1997,6(1):27-30. 被引量：29
-
8石松魁,郎义芳,傅西林,李瑞英,方志沂,宁连胜,马淑资,李云英,刘俊田,朱元喜.0～Ⅱ期乳腺癌外科保守治疗的疗效观察[J].中国肿瘤临床,2002,29(1):46-48. 被引量：27
共引文献36
-
1刘玉贵.保乳手术综合治疗乳腺癌63例分析[J].临床医药实践,2007,16(11):1077-1078. 被引量：2
-
2雷玉涛,赵红梅,侯宽永.乳腺癌保乳手术方式的选择[J].中国微创外科杂志,2004,4(4):296-297. 被引量：13
-
3赵晶,方志沂.乳腺癌保乳术后复发及转移的分子生物学相关因素[J].中国肿瘤临床,2004,31(15):897-899. 被引量：3
-
4陈龙舟.早期乳腺癌32例分析[J].河北医学,2004,10(9):814-816.
-
5范永红,包荣,石松魁,宋志军,潘汉东,白涛.保留乳房的乳腺癌根治术24例[J].包头医学院学报,2003,19(4):293-294.
-
6张文芳,高云.乳腺癌保乳手术后复发和转移的相关因素[J].医学综述,2005,11(2):136-138.
-
7刘君,方志沂,于泳,赵晶,郝希山.乳腺癌保乳手术安全范围的研究[J].中国肿瘤临床,2005,32(15):856-860. 被引量：36
-
8全宝库,刘微,杨学伟.乳腺癌保乳治疗的现状[J].齐齐哈尔医学院学报,2005,26(10):1185-1186. 被引量：4
-
9刘森,王牧.保乳手术综合治疗乳腺癌[J].实用临床医学（江西）,2006,7(2):147-148.
-
10牛江平,张续民.保乳手术治疗早期乳腺癌31例[J].陕西医学杂志,2006,35(6):673-674. 被引量：2
-
1杨新平（综述）,陶叠宏（综述）,陈国安（审校）.否决细胞与免疫耐受的诱导[J].国际移植与血液净化杂志,2007,5(2):39-41.
-
2王仁定.供体骨髓输注在肾脏移植耐受中的疗效和机制[J].国外医学（免疫学分册）,2003,26(2):66-69. 被引量：1
-
3陈国安,袁利亚,何飞.造血干细胞嵌合体诱导移植免疫耐受[J].生命科学,2003,15(5):262-265. 被引量：1
-
4商文聪,杨荣存.髓系免疫抑制细胞的研究进展[J].中国免疫学杂志,2016,32(6):922-928. 被引量：3
